IFEC   20925
INSTITUTO DE FARMACOLOGIA EXPERIMENTAL DE CORDOBA
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Neuroprotective effect of estradiol in a Parkinson?s disease model on female rats: motor dysfunctions, brain derived neurotrophic factor (BDNF) and 𝜶-synuclein expression and striatal dopamine release
Autor/es:
HERRERA MACARENA; CABRERA RICARDO; YUNES ROBERTO; GIULIANI FERNANDO
Lugar:
Ribeirao Preto
Reunión:
Jornada; XXI Curso de Verano en genética; 2016
Institución organizadora:
Departamento de Posgraduación en Genética-USP
Resumen:
Neuroprotective effect of estradiol in a Parkinson?s disease model on female rats: motor dysfunctions, BDNF and α-synuclein expression and striatal dopamine release.Macarena Herrera1*; Fernando Giuliani1; Roberto Yunes1; Ricardo Cabrera1. 1. Instituto de Investigaciones Biomédicas-Universidad de Mendoza-Instituto de Medicina y Biología Experimental de Cuyo-CCT Mendoza-CONICET. Argentina.*macarenalherrera@hotmail.comBACKGROUND: Parkinson?s disease (PD) is the second most common neurodegenerative disorder, with a prevalence that is higher in men than women. This has raised the hypothesis that female hormones could have neuroprotective properties. Their actions might be evidenced as improvements in the motor symptoms as well as changes in the expression of neurotrophic factors, in the neuronal activity of the affected brain areas and in the expression of protein aggregates α-syn (Lewis Body inclusions). OBJECTIVES: To determine in an experimental model of the neuropathology (hemiparkinsonian rats) if estradiol (E) treatment could: 1) improve the motor dysfunctions; 2) induce changes in the striatal mRNA expression of BDNF and α-syn; and 3) modify the striatal dopamine release. METHODS: We used ovariectomized adult rats that were unilaterally injected in right corpus striatum with either the neurotoxic 6-hydroxydopamine (HP rats), or vehicle (sham rats) as controls. Five days after lesion they were treated with a subcutaneous daily treatment of either 0.1µg/kg estradiol (HP-E group) or vehicle (HP-group and sham-group) for 10 consecutive days. To assess the objective 1, eight weeks after lesion we assayed for each rat stepping, curling and apomorphine-induced turning behavior tests. After that, we killed them by decapitation and dissected out the corpus striata. A subset of each tissue was assigned to mRNA extraction and ulterior RTqPCR of BDNF and RTPCR of α-syn (objective 2). The other subset was separated to superfusion assays with [3H]-dopamine to study the ex vivo K+-evoked release of this neurotransmitter (objective 3). All data were compared by 1-way ANOVA (p